Preclinical Autoimmune & Immunology Services
Success in autoimmune and immunology drug discovery depends on selecting the right experimental systems, generating translational data early, and understanding how drug candidates modulate complex immune pathways, in both a drug efficacy and drug safety context. By combining disease-relevant models, human immune cell assays, biomarker strategies, and mechanistic insights, we generate data that supports confident decision-making at every stage of development.
Whether you are developing biologics, cell therapies, antibody-based therapeutics, peptides, or small molecules, our team helps you evaluate efficacy, pharmacology, safety and immune function within a framework focused on clinical translation.
Diseases Supported By Preclinical Autoimmune and Immunology Services
Our preclinical autoimmune and immunology services are applied across a broad range of diseases, including:
Asthma
Leverage validated in vivo models and translational endpoints to assess the therapeutic efficacy of novel drugs targeting respiratory inflammation and immune response.
Atopic Dermatitis
Evaluate therapies targeting the pathways regulating inflammation and Th1 to Th2 bias in translational atopic dermatitis models.
Autoimmune Uveitis
Experimental autoimmune uveitis models support the investigation of intraocular inflammation and retinal damage, enabling evaluation of novel therapeutics.
Contact Dermatitis
Contact dermatitis models provide translational platforms for evaluating therapies in both allergic and irritant skin inflammation, with acute and chronic study options available.
Immuno-Oncology
Optimized immune cell assays and translational in vivo models support the discovery and development of therapies targeting the immune system to treat cancer.
Inflammatory Bowel Disease
Evaluate therapeutic approaches designed to reduce inflammation, restore tissue integrity, and regulate immune pathways involved with Crohn's disease and ulcerative colitis
Multiple Sclerosis
Assess immune-mediated mechanisms and therapeutic potential in the experimental autoimmune encephalomyelitis (EAE) model using a multidisciplinary approach.
Neuroinflammation
Explore the therapeutic potential of targeting neuroinflammatory pathways in complex in vitro human cell-based assays with disease-relevant challenges and induced in vivo models.
Psoriasis
Measure the impact of emerging therapies on the immune mechanisms underlying psoriasis and other chronic inflammatory skin conditions.
Rheumatoid Arthritis
Evaluate therapies targeting immune pathways that drive joint inflammation, tissue damage, and disease progression in rheumatoid arthritis and related rheumatologic disorders.
Scleroderma
Explore the potential of immunomodulation in treating skin scleroderma in the bleomycin-induced model.
Systemic Lupus Erythematosus
Generate translational data to support the development of therapies targeting the complex immune dysregulation underlying lupus.
In Vitro Immunology
Our integrated in vitro immunology services combine mechanism-of-action studies, immune cell profiling, biomarker identification, immunogenicity assessment, and predictive immunotoxicology. Using physiologically relevant assays across key immune cell types and advanced co-culture systems, we generate translational insights for immunology, inflammation, autoimmune, immuno-oncology, and cell and gene therapy programs.
Our integrated platform supports immunology programs across multiple stages of drug discovery, generating multi-dimensional data that supports therapeutic efficacy decisions.
Biomarker analysis
Identify and validate translational biomarkers that support greater understanding of target engagement and therapeutic efficacy.
Flow cytometry and immune profiling
Isolate and characterize immune cell populations and treatment responses in complex biological samples.
Molecular and Genomic Analysis
Generate deep insights into autoimmune, immunology and inflammation pathways, and mechanisms for therapeutic targeting.
Pharmacodynamic endpoints
Assess target engagement in immunology and autoimmune-specific pharmacodynamic models prior to testing in costly disease models.
Humanized models
Models with a humanized immune system enable stronger translation and safety assessment, bridging the gap between in vitro assays and clinical trials
The complexity of the immune system demands an integrated discovery strategy. Our scientific teams work closely with you to align assay selection, model design, and biomarker analysis with your therapeutic hypothesis and modality, enabling better decisions earlier and advancing the most promising candidates with greater confidence.
Rather than generating isolated data points, we create connected evidence packages that answer critical development questions:
- Is the target biologically relevant in the disease context?
- Is the therapeutic engaging the intended immune pathway?
- Which biomarkers best demonstrate pharmacological activity?
- Does efficacy correlate with immune modulation?
- How can preclinical findings support clinical translation?
Why Partner With Us for Preclinical Immunology Services?
Deep Scientific Expertise
Our multidisciplinary teams include immunologists, pharmacologists, biomarker specialists, and translational scientists with extensive experience across immunology and autoimmune diseases.
Integrated Study Design
We combine in vitro, ex vivo, and in vivo capabilities within a single program to streamline development and reduce project complexity.
Translational Focus
Every study is designed to generate insights that bridge preclinical findings and clinical outcomes.
Flexible Support Models
From standalone assays to fully integrated discovery programs, we tailor solutions to your scientific objectives, timelines, and development milestones.
Frequently Asked Questions
What are preclinical immunology services?
Preclinical immunology services provide the scientific capabilities needed to evaluate immune-related drug candidates before toxicology studies and clinical trials. These services typically include immunology assays, pharmacology studies, biomarker analysis, immune profiling, and disease-relevant efficacy models.
Why are preclinical immunology services important in drug discovery?
Immunology-focused studies help researchers understand target biology, evaluate mechanism of action, identify biomarkers, and assess therapeutic efficacy. Early immunology data can improve candidate selection and reduce development risk before clinical testing.
What types of therapies can benefit from preclinical immunology services?
These services support a wide range of modalities, including monoclonal antibodies, bi- or multi-specific antibodies, antibody-drug conjugates, cell therapies, gene therapies, peptides, vaccines, and small-molecule therapeutics.
How do translational biomarkers improve immunology research?
Translational biomarkers provide measurable evidence that a therapy is affecting the intended biological pathway. They help connect preclinical findings to anticipated clinical outcomes and support dose selection and study design decisions.
What should be considered when selecting an autoimmune or inflammation model?
Model selection should be based on the therapeutic target, mechanism of action, relevant immune pathways, and intended clinical indication. The most effective models provide meaningful biological relevance and support translational interpretation of results.
Can preclinical immunology services support both early discovery and IND-enabling programs?
Yes. Immunology services can be applied throughout the development continuum, from target validation and lead optimization to candidate selection, translational research, and preparation for clinical studies.
What makes a translational immunology strategy successful?
Successful programs combine relevant biological models, robust biomarker approaches, mechanistic understanding, and clinically meaningful endpoints. This integrated strategy helps generate evidence that supports progression into human studies.
